Doxycycline and airway inflammation in COPD A randomised placebo controlled cross-over trial in patients with GOLD III COPD

Conditions: COPD
lung emphysema
10006436

Registration Number: NL-OMON31738

Lead Sponsor: Medisch Centrum Alkmaar

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: Not specified

Target Recruitment: 40

Inclusion Criteria

• GOLD II COPD (FEV1/FVC < 70%; 50% < FEV1 < 80% predicted).
• Stable disease (no exacerbations in the last 3 months).
• Age >40 yrs.
• Written informed consent.

Exclusion Criteria

• Infections and/or use of antibiotics in the last month.
• Allergy for tetracyclines or a history of substantial side-effects.
• Active respiratory diseases other than COPD (e.g. sarcoidosis, tuberculosis, lung cancer, bronchiectasis).
• Signs and/or symptoms consistent with an acute exacerbation of COPD (AECOPD), such as increase in dyspnea, increase in sputum volume or change of sputum color from mucoid to purulent.
• Signs and/or symptoms of a current respiratory or non-respiratory infection.
• Use of oral or intravenous corticosteroids or other immunosuppressive drugs within the last month.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Change in sputum IL-6 levels </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Change in FEV1<br /><br>Change in markers of neutrophil activation/activity (IL-8, MMP-8, MMP-9 and<br /><br>MPO), T cell activation (granzyme A and perforin) and monocyte activation<br /><br>(TNF-a, IL-1, cathepsin K </p><br>